Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares are down on Tuesday as the company reported mixed results from its Phase 3 SENTRY trial for myelofibrosis.Myelofibrosis is a rare, chronic blood cancer (myeloproliferative neoplasm) where bone marrow is replaced by scar tissue, disrupting blood cell production.Trial Shows Strong Spleen Reduction But Misses Symptom EndpointThe SENTRY trial met its first co-primary endpoint, showing significant improvement in spleen volume reduction for patients treated with s ...